ID   Ff-XT28s05
AC   CVCL_C1EB
SY   Ff-XT 28s05
DR   Wikidata; Q114311429
RX   Patent=US20200407693;
RX   PubMed=30853558;
RX   PubMed=31497180;
RX   PubMed=36395757;
CC   Part of: Japanese HLA-homozygous iPS cell line panel.
CC   From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan.
CC   Population: Japanese.
CC   HLA typing: A*24:02; B*07:02; DRB1*01:01; DQB1*05:01; DRB1*01:01 (PubMed=30853558).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C1E3 ! DRXT18s02
OI   CVCL_C1E4 ! DRXT18s03
OI   CVCL_C1E5 ! DRXT28s04
OI   CVCL_C1E6 ! DRXT28s05
OI   CVCL_C1E7 ! DRXT28s17
OI   CVCL_C1E8 ! Ff-XT18s02
OI   CVCL_C1E9 ! Ff-XT18s03
OI   CVCL_C1EA ! Ff-XT28s04
OI   CVCL_C1EC ! Ff-XT28s17
SX   Male
AG   Age unspecified
CA   Induced pluripotent stem cell
DT   Created: 22-09-22; Last updated: 02-05-24; Version: 5
//
RX   Patent=US20200407693;
RA   Hotta A., Xu H.-G., Kaneko S., Wang B.;
RT   "Method for producing low-antigenic cell.";
RL   Patent number US20200407693, 31-Dec-2020.
//
RX   PubMed=30853558; DOI=10.1016/j.stem.2019.02.005;
RA   Xu H.-G., Wang B., Ono M., Kagita A., Fujii K., Sasakawa N., Ueda T.,
RA   Gee P., Nishikawa M., Nomura M., Kitaoka F., Takahashi T., Okita K.,
RA   Yoshida Y., Kaneko S., Hotta A.;
RT   "Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with
RT   enhanced immune compatibility.";
RL   Cell Stem Cell 24:566-578.e7(2019).
//
RX   PubMed=31497180; DOI=10.1186/s41232-019-0106-0; PMCID=PMC6717959;
RA   Umekage M., Sato Y., Takasu N.;
RT   "Overview: an iPS cell stock at CiRA.";
RL   Inflamm. Regen. 39:17.1-17.5(2019).
//
RX   PubMed=36395757; DOI=10.1016/j.medj.2022.10.003;
RA   Yoshida S., Kato T.M., Sato Y., Umekage M., Ichisaka T., Tsukahara M.,
RA   Takasu N., Yamanaka S.;
RT   "A clinical-grade HLA haplobank of human induced pluripotent stem
RT   cells matching approximately 40% of the Japanese population.";
RL   Med 4:51-66.e10(2023).
//